No Data
BAIYUNSHAN PH (600332.SH): Sodium cefazolin for injection passed the consistency evaluation of generic drugs.
On December 13th, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that its controlling subsidiary, Guangzhou BAIYUNSHAN TIANXIN Pharmaceutical Co., Ltd., received the "Notice of Approval for Supplementary Application of Pharmaceutical" issued by the National Medical Products Administration, indicating that injectable Cefazolin Sodium (1.0g, 0.5g) has passed the consistency evaluation of quality and efficacy for generic drugs. Cefazolin Sodium is a third-generation cephalosporin, primarily used to treat lower respiratory tract infections, urinary tract infections, intra-abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae, and mon...
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Baiyunshan (00874.HK) saw a shareholding reduction of 0.348 million shares by Norges Bank.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on November 27, 2024, baiyunshan ph (00874.HK) was sold by Norges Bank on the exchange at an average price of HKD 18.0525 per share, selling 0.348 million shares, involving approximately 6.2823 million Hong Kong dollars. After the shareholding, Norges Bank's latest number of shares held is 10.855 million shares, and the shareholding ratio has decreased from 5.09% to 4.94%.
Baiyunshan (00874.HK)'s subsidiary Guangzhou Medicine sells the first new underlying assets to Xingzheng Asset Management and receives a purchase price of 0.524 billion yuan.
Gelonghui reported on November 28 that baiyunshan ph (00874.HK) announced that on November 28, 2024, the company's non-wholly-owned subsidiary Guangzhou Medicine signed a "New Basic Asset Delivery Confirmation Letter" with Xingzheng Asset Management according to the Basic Asset Sale Agreement (Phase IV), confirming the sale of the first newly added basic asset to Xingzheng Asset Management and receiving a purchase price of 524,000,713.50 yuan.
Baiyunshan Pharma's Unit Gets Nod to Make Changes to Selaginella Jiangnanensis Tablets
Baiyunshan Pharma Gets Nod to Market Anti-Tumor Drug
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
No Data
